Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for XCUR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 -0.887M
March 31, 2026 -1.142M
December 31, 2025 -0.934M
September 30, 2025 -3.422M
June 30, 2025 -2.602M
March 31, 2025 -1.598M
December 31, 2024 -0.845M
September 30, 2024 -0.449M
June 30, 2024 -1.166M
March 31, 2024 -0.45M
December 31, 2023 -0.816M
September 30, 2023 -1.412M
June 30, 2023 -4.811M
March 31, 2023 -3.318M
December 31, 2022 -7.276M
September 30, 2022 -6.548M
June 30, 2022 -9.082M
March 31, 2022 -13.27M
Date Value
December 31, 2021 -14.14M
September 30, 2021 4.804M
June 30, 2021 -11.42M
March 31, 2021 -15.03M
December 31, 2020 -11.90M
September 30, 2020 -8.627M
June 30, 2020 -13.49M
March 31, 2020 -8.424M
December 31, 2019 14.71M
September 30, 2019 -5.365M
June 30, 2019 -5.09M
March 31, 2019 -4.02M
December 31, 2018 -5.992M
September 30, 2018 -4.198M
June 30, 2018 -4.744M
March 31, 2018 -4.647M
December 31, 2017 -5.542M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Tenax Therapeutics, Inc. -14.15M
Manhattan Scientifics, Inc. --
Century Therapeutics, Inc. -20.53M
Absci Corp. -27.56M
Celularity, Inc. -5.103M